Latest News

SCOUT-HCM: Mavacamten Achieves Positive Results in Adolescents with Obstructive HCM

1 hour ago

Bristol Myers Squibb has reported positive results from the ongoing SCOUT-HCM trial, demonstrating mavacamten’s efficacy in reducing Valsalva LVOT.

Low Exercise Tolerance Before Kidney Transplant Signals Poor Muscle Recovery

1 hour ago

A retrospective analysis links low pretransplant exercise tolerance with reduced skeletal muscle recovery and persistent sarcopenia risk after living donor kidney transplantation in CKD.

Tegoprazan NDA Seeks FDA Approval for 3 GERD Indications

2 hours ago

The NDA is supported by data from the phase 3 TRIUMpH clinical program and seeks approval for heartburn in NERD, healing of erosive esophagitis, and maintenance of healing.

Predictors Identified for Super-Responder Status to Dupilumab in Atopic Dermatitis

2 hours ago

In this retrospective single-center analysis, adult patients with moderate-to-severe atopic dermatitis treated with dupilumab were evaluated for super responder status.

Quality of Life and GI Tolerability in ATTR-CM Management

3 hours ago

The panel focuses on how quality of life considerations shape ATTR-CM management. Beyond survival and hospitalization outcomes, many patients most value being able to remain mobile and independent—continuing activities such as walking, gardening, or caring for grandchildren. Even subjective concerns like weight loss or appearing “frail” can meaningfully affect how patients feel about their health. Managing symptoms of congestion and reducing the need for frequent diuretic adjustments also plays an important role in daily well-being. The discussion then highlights recent data from HFSA showing that vutrisiran was associated with fewer gastrointestinal symptoms, such as diarrhea and constipation. The panel found this particularly interesting in wild-type ATTR-CM, where GI involvement is not always recognized. Improvements in GI comfort can support better nutrition, energy, and overall day-to-day function. Across the conversation, the experts emphasize that maintaining function and stability over time is often the clinical outcome patients value most.

Evaluating Long-Term Remission and Disease Control with Bimekizumab in Psoriasis

January 12, 2026

3 hours ago

In this episode, the panelists review long-term efficacy data for bimekizumab presented at EADV 2025, focusing on sustained remission and disease control in psoriasis. The experts highlight that approximately 49% of patients maintained complete skin clearance (PASI 100) from month 4 through year 4, with about 72% sustaining complete or near-complete clearance over the same period. They interpret these findings as strong evidence of durability and depth of response, underscoring bimekizumab’s ability to maintain remission over years rather than months. The discussion also includes nail outcomes, with nearly 80% of patients maintaining NAPSI 0, indicating resolution of nail involvement—an important factor given its association with psoriatic arthritis risk. The panelists emphasize that by achieving and maintaining high levels of clearance in both skin and nails, bimekizumab may help interrupt the inflammatory progression that leads to PsA, reinforcing its role in comprehensive disease control.

Severe Pediatric Dermatoses: Diagnostic Pitfalls and Early Systemic Therapy

January 12, 2026

3 hours ago

Explore diagnostic challenges in severe pediatric skin disease, common management pitfalls, and when to escalate to systemic or biologic therapy.

Clinical Considerations for Monotherapy vs Dual Therapy in ATTR-CM Management

January 12, 2026

3 hours ago

The panel discusses decision-making around monotherapy versus dual therapy in ATTR-CM. They explain that while there is not definitive, statistically significant evidence supporting routine dual therapy for all patients, there is also no evidence of harm when stabilizers and silencers are used together. Because the two therapeutic classes work through different mechanisms, dual therapy is considered reasonable in selected patients, particularly when the goal is to slow progression as much as possible. The panel emphasizes that treatment decisions should be individualized, guided by disease stage, symptom burden, neurologic involvement, patient priorities, and access considerations. They stress that ATTR-CM is not a uniform disease, and two patients with the same diagnosis may have completely different clinical needs. Ultimately, the group agrees that the only clearly inappropriate choice is providing no disease-modifying therapy at all.

Non-Opioid ST-01 Provides Sustained Pain Relief in Chronic Scrotal Pain

January 12, 2026

3 hours ago

Repeat monthly dosing of sustained-release lidocaine ST-01 met primary and secondary endpoints in phase 2 trial, delivering durable pain relief in men with chronic scrotal pain.

Redefining Treatment Success and Remission in Psoriasis Care

January 12, 2026

3 hours ago

In this episode, the panelists discuss how the definition of treatment success and remission in psoriasis has evolved. Historically, achieving PASI 75 was considered adequate, but the experts explain that PASI 100, or complete skin clearance, is now the preferred benchmark. They reference the National Psoriasis Foundation’s 2025 consensus statement, which defines remission as maintaining ≤1% body surface area involvement for at least six months and a DLQI score of 0 or 1, indicating no impact on quality of life. The panelists emphasize that complete skin clearance reflects a deeper suppression of systemic inflammation and may reduce the risk of psoriatic arthritis. They also highlight that visible clearance serves as a practical measure in the absence of validated biomarkers. With current systemic therapies making PASI 100 an attainable goal, the experts agree that striving for sustained remission represents both clinical success and improved long-term outcomes.

Q4 2025 Recap: Hematology News and Updates

January 11, 2026

January 11, 2026

The Q4 recap for cardiology spotlights major FDA decisions, key clinical trial updates, and more.

New Topline Phase 3 Data on Zasocitinib in Psoriasis, With Melinda Gooderham, MD

January 10, 2026

January 10, 2026

In her interview, Melinda Gooderham, MD, highlights the impact of recent topline findings on zasocitinib, a once-daily pill for adults with psoriasis.

Phase 3 Trial Supports Subcutaneous Anifrolumab in Systemic Lupus Erythematosus

January 10, 2026

January 10, 2026

Subcutaneous anifrolumab for SLE met its primary BICLA endpoint at 52 weeks and significantly increased DORIS-defined remission and low disease activity.

The HCPFive: Top News for Healthcare Providers from the Week of 01/04

January 10, 2026

January 10, 2026

Stay updated with the latest healthcare breakthroughs, including FDA approvals and other regulatory updates, in this week’s essential news roundup.

Evinacumab May Lower Triglycerides in Severe Hypertriglyceridemia, With Robert Rosenson, MD

January 10, 2026

January 10, 2026

Rosenson explains the data gained from a terminated phase 2b trial, highlighting evinacumab’s potential as a triglyceride-lowering therapy.

Advertisement

Advertisement